Gujarat Themis Biosyn
- Market cap
- ₹ 4,234 Cr.
- P/E
- 95x
- P/B
- 13.38x
- 52-week range
- 225.05 – 471.8
- ROE
- 17%
- ROCE
- 18%
- Dividend yield
- 0.2%
- Debt / equity
- 0.56
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The Company operates through pharmaceuticals segment. Its product portfolio comprises Rifamycin-S and Lovastatin. The Company is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy).
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Gujarat Themis Biosyn against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)95 against a typical 34.3: pricier than most peers (1st = cheapest).191st of 220
- Sales growth+22.2% against a typical +15.6% from a year earlier.72nd of 197
- Profit growth+22.2% against a typical +18.9% from a year earlier.77th of 160
- Share price, 3 months−0.1% against a typical −0.5%.99th of 200
- Size₹ 4,233.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).57th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB (Rating Watch with Negative Implications) | — | 15 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 15 Jul 2026 | Reaffirmed | CARE BBB → CARE BBB (Rating Watch with Negative Implications) | — | CARE | ₹ 80 Cr. | |
| 18 Feb 2026 | Reaffirmed | CARE BBB | — | CARE | ₹ 80 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results | To consider and approve the un-audited standalone and consolidated financial results for the period ended September 30, 2026 |
| 10 Sep 2026 | Fund Raising | To consider Fund Raising |
| 1 Sep 2026 | Fund Raising | To consider Fund Raising |
| 7 Aug 2026 | Financial Results/Fund Raising | To consider and approve the financial results for the period ended Jun 30, 2026 and Fund Raising |
| 19 Jun 2026 | Board meeting Rescheduled | Gujarat Themis Biosyn Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled to be held on Jun 19, 2026 To consider Fund Raising has been postponed |
| 6 Jun 2026 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 25 May 2026 | Fund Raising | To consider Fund Raising |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | 44 |
| Expenses | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | 23 |
| Operating Profit | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | 21 |
| OPM % | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | 48% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | 4 |
| Profit before tax | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | 15 |
| Tax % | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | 27% |
| Net Profit | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | 11 |
| EPS in Rs | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.1 | 0.83 | 1.31 | 1.14 | 1 | 1.02 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 18%
- 5 Years
- 13%
- 3 Years
- 4%
- TTM
- 18%
- 10 Years
- 26%
- 5 Years
- 9%
- 3 Years
- −7%
- TTM
- 9%
- 10 Years
- 49%
- 5 Years
- 45%
- 3 Years
- 51%
- TTM
- —
- 10 Years
- 32%
- 5 Years
- 29%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gujarat Themis Biosyn | ₹ 356.50 | ₹ 4,234 Cr. | 95x | 13.4x | 17% | — |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
Management
- Krupesh Patel
- Chief Financial Officer
- Vineet G. Gawankar
- Chief Compliance Officer, Company Secretary
- Sachin Dinesh Patel
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.